A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson's disease using an ambulatory monitor

J Neuroeng Rehabil. 2021 Jul 16;18(1):116. doi: 10.1186/s12984-021-00905-4.

Abstract

Background: Fluctuations in motor function in Parkinson's Disease (PD) are frequent and cause significant disability. Frequently device assisted therapies are required to treat them. Currently, fluctuations are self-reported through diaries and history yet frequently people with PD do not accurately identify and report fluctuations. As the management of fluctuations and the outcomes of many clinical trials depend on accurately measuring fluctuations a means of objectively measuring time spent with bradykinesia or dyskinesia would be important. The aim of this study was to present a system that uses wearable sensors to measure the percentage of time that bradykinesia or dyskinesia scores are above a target as a means for assessing levels of treatment and fluctuations in PD.

Methods: Data in a database of 228 people with Parkinson's Disease and 157 control subjects, who had worn the Parkinson's Kinetigraph ((PKG, Global Kinetics Corporation™, Australia) and scores from the Unified Parkinson's Disease Rating Scale (UPDRS) and other clinic scales were used. The PKG's provided score for bradykinesia and dyskinesia every two minutes and these were compared to a previously established target range representing a UPDRS III score of 35. The proportion of these scores above target over the 6 days that the PKG was worn were used to derive the percent time in bradykinesia (PTB) and percent time in dyskinesia (PTD). As well, a previously describe algorithm for estimating the amplitude of the levodopa response was used to determine whether a subject was a fluctuator or non-fluctuator.

Results: Using this approach, a normal range of PTB and PTD based on Control subject was developed. The level of PTB and PTD experienced by people with PD was compared with their levels of fluctuation. There was a correlation (Pearson's ρ = 0.4) between UPDRS II scores and PTB: the correlation between Parkinson Disease Questionnaire scores and UPDRS Total scores and PTB and slightly lower. PTB and PTD fell in response to treatment for bradykinesia or dyskinesia (respectively) with greater sensitivity than clinical scales.

Conclusions: This approach provides an objective assessment of the severity of fluctuations in Parkinson's Disease that could be used in in clinical trials and routine care.

Keywords: Fluctuations; Objective measurement; Off-time; Parkinson’s; Sensors; Wearing-off.

MeSH terms

  • Algorithms
  • Antiparkinson Agents
  • Dyskinesias* / diagnosis
  • Dyskinesias* / etiology
  • Humans
  • Hypokinesia / diagnosis
  • Hypokinesia / etiology
  • Levodopa
  • Parkinson Disease* / complications
  • Parkinson Disease* / drug therapy

Substances

  • Antiparkinson Agents
  • Levodopa